CDNA insider plans sale of 7,000 shares

CDNA insider Peter Maag filed to sell 7,000 shares of common stock through Morgan Stanley Smith Barney LLC Executive Financial Services, with an indicated value of $329,505.40 on NASDAQ.

Rhea-AI Filing Summary

CDNA insider Peter Maag filed to sell 7,000 shares of common stock through Morgan Stanley Smith Barney LLC Executive Financial Services, with an indicated value of $329,505.40 on NASDAQ. The shares relate to restricted stock granted as compensation on 04/11/2023, 01/29/2024, and 02/03/2024. The filing also lists several recent sales, including 7,000 shares for $333,851.00 on 08/11/2026 and 75,653 shares for $3,576,851.19 on 08/04/2026.

Key Figures

Planned shares to be sold: 7,000 shares Planned sale value: $329,505.40 Recent sale 08/11/2026: 7,000 shares for $333,851.00 +4 more

7 metrics

Planned shares to be sold 7,000 shares Common stock to be sold through Morgan Stanley Smith Barney LLC Executive Financial Services

Planned sale value $329,505.40 Indicated value of 7,000 shares of common stock on NASDAQ

Recent sale 08/11/2026 7,000 shares for $333,851.00 Common stock sale by Peter Maag

Recent sale 08/04/2026 75,653 shares for $3,576,851.19 Common stock sale by Peter Maag

Restricted stock grant 01/29/2024 3,797 shares Restricted stock from issuer listed as compensation

Restricted stock grant 04/11/2023 1,256 shares Restricted stock from issuer listed as compensation

Restricted stock grant 02/03/2024 1,947 shares Restricted stock from issuer listed as compensation

Key Terms

Restricted Stock, Compensation, Executive Financial Services

3 terms

Restricted Stock financial

"Common | 01/29/2024 | Restricted Stock | Issuer"

Shares granted to an individual that carry limits on transfer or sale until certain conditions are met, such as staying with the company for a set time or hitting performance targets. Think of them as a locked gift that gradually opens; for investors they matter because they affect how many shares may enter the market later, signal management incentives and potential dilution, and reveal confidence in future company performance.

Compensation financial

"3797 | 01/29/2024 | Compensation Common | 04/11/2023"

Executive Financial Services financial

"Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does CDNA’s Form 144 filing by Peter Maag disclose?

The filing shows Peter Maag plans to sell 7,000 CDNA common shares via Morgan Stanley Smith Barney LLC Executive Financial Services, with an indicated value of $329,505.40, and lists several recent open-market sales of CDNA shares.

How many CDNA shares is Peter Maag planning to sell under this Form 144?

Peter Maag is planning to sell 7,000 shares of CDNA common stock. The filing lists these shares with an aggregate value of $329,505.40 and identifies Morgan Stanley Smith Barney LLC Executive Financial Services as the broker handling the transaction.

Which recent CDNA stock sales by Peter Maag are reported in the Form 144?

Reported recent CDNA sales include 7,000 shares for $333,851.00 on 08/11/2026 and 75,653 shares for $3,576,851.19 on 08/04/2026, along with several other transactions in August 2026, each with specified share counts and dollar amounts.

What is the source of the CDNA shares in Peter Maag’s Form 144 filing?

The shares trace to restricted stock granted as compensation by the issuer. The filing lists awards dated 04/11/2023 (1,256 shares), 01/29/2024 (3,797 shares), and 02/03/2024 (1,947 shares) as securities to be sold.

Which broker is handling Peter Maag’s planned CDNA share sale?

The planned sale of 7,000 CDNA shares is through Morgan Stanley Smith Barney LLC Executive Financial Services, located at 1 New York Plaza, 8th Floor, New York, NY 10004, as specified in the Form 144 filing.

On which market are Peter Maag’s CDNA shares listed according to the Form 144?

The shares referenced in the filing are listed on NASDAQ. The Form 144 indicates NASDAQ as the trading market for the CDNA common stock that Peter Maag has sold recently and plans to sell.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/13/2026 - 04:20 PM Accepted by SEC EDGAR 08/13/2026 - 04:19 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001613855
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	CAREDX, INC.
SEC File Number	001-36536
Address of Issuer	8000 Marina Boulevard, Brisbane CALIFORNIA 94005
Phone	415-287-2300
Name of Person for Whose Account the Securities are To Be Sold	PETER MAAG
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	7000	329505.40	51734223	08/13/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	01/29/2024	Restricted Stock	Issuer			3797	01/29/2024	Compensation
Common	04/11/2023	Restricted Stock	Issuer			1256	04/11/2023	Compensation
Common	02/03/2024	Restricted Stock	Issuer			1947	02/03/2024	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
PETER MAAG 8000 Marina Boulevard, Brisbane CA 94005	Common	08/12/2026	7000	328237.70
PETER MAAG 8000 Marina Boulevard, Brisbane CA 94005	Common	08/11/2026	7000	333851.00
PETER MAAG 8000 Marina Boulevard, Brisbane CA 94005	Common	08/10/2026	6902	328949.32
PETER MAAG 8000 Marina Boulevard, Brisbane CA 94005	Common	08/07/2026	27332	1252491.63
PETER MAAG 8000 Marina Boulevard, Brisbane CA 94005	Common	08/05/2026	46963	2178945.34
PETER MAAG 8000 Marina Boulevard, Brisbane CA 94005	Common	08/04/2026	75653	3576851.19

144: Remarks and Signature

Remarks
Date of Notice	08/13/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Peter Maag
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)